Irregularly shaped inclusion cysts display increased expression of Ki67, Fas, Fas ligand, and procaspase-3 but relatively little active caspase-3

International Journal of Gynecological Cancer

Volumn 16, Issue 1, 2006, Pages 231-239

  Slot, K A ^a   De Boer Brouwer, M ^a   Voorendt, M ^a   Sie Go, D M D S ^b   Ghahremani, M ^c   Dorrington, J H ^c   Teerds, K J ^a,d  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY OF TORONTO   (Canada)

^d WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

Apoptosis; Fas system; Inclusion cysts; Ovarian cancer; Proliferation

Indexed keywords

BIOLOGICAL MARKER; CASPASE 3; FAS ANTIGEN; FAS LIGAND; KI 67 ANTIGEN; PROCASPASE 3;

ADULT; AGED; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL DEATH; CELL GROWTH; CELL INCLUSION; CELL PROLIFERATION; CELL STRUCTURE; CELL TYPE; CONTROLLED STUDY; CYST; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; INHIBITION KINETICS; OVARY; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTIGENS, CD95; CASE-CONTROL STUDIES; CASPASE 3; CASPASES; CELL PROLIFERATION; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; OVARIAN CYSTS; OVARIAN NEOPLASMS; OVARIECTOMY; OVARY; PROBABILITY; PROGNOSIS; REFERENCE VALUES; SAMPLING STUDIES; SENSITIVITY AND SPECIFICITY; TISSUE CULTURE TECHNIQUES; TUMOR MARKERS, BIOLOGICAL;

EID: 33645338718     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00465.x     Document Type: Article

References (34)

1. Scully RE. Pathology of ovarian cancer precursors. J Cell Biochem Suppl 1995 23 208 18.
2. Fathalla MF. Incessant ovulation - a factor in ovarian neoplasia? Lancet 1971 2 163.
3. Godwin AK Testa JR Hamilton TC. The biology of ovarian cancer development. Cancer 1993 71 530 6.
4. Whittemore AS Harris R Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992 136 1212 20.
5. Cramer DW Welch WR. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 1983 71 717 21.
6. Auersperg N Wong AS Choi KC Kang SK Leung PC. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 2001 22 255 88.
7. Ghahremani M Foghi A Dorrington JH. Etiology of ovarian cancer: a proposed mechanism. Med Hypotheses 1999 52 23 6.
8. Ben Hur H Gurevich P Huszar M et al. Apoptosis and apoptosis-related proteins in the epithelium of human ovarian tumors: immunohistochemical and morphometric studies. Eur J Gynaecol Oncol 1999 20 249 53.
9. Chan WY Cheung KK Schorge JO et al. Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers. Am J Pathol 2000 156 409 17.
10. Munakata S Enomoto T Tsujimoto M et al. Expressions of Fas ligand and other apoptosis-related genes and their prognostic significance in epithelial ovarian neoplasms. Br J Cancer 2000 82 1446 52.
11. Wehrli BM Krajewski S Gascoyne RD Reed JC Gilks CB. Immunohistochemical analysis of bcl-2, bax, mcl-1, and bcl-X expression in ovarian surface epithelial tumors. Int J Gynecol Pathol 1998 17 255 60.
12. Kupryjanczyk J Thor AD Beauchamp R et al. p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci U S A 1993 90 4961 5.
13. Sengupta PS McGown AT Bajaj V et al. p53 and related proteins in epithelial ovarian cancer. Eur J Cancer 2000 36 2317 28.
14. Krammer PH. CD95 (APO-1/Fas)-mediated apoptosis: live and let die. Adv Immunol 1999 71 163 210.
15. Das H Koizumi T Sugimoto T et al. Quantitation of Fas and Fas ligand gene expression in human ovarian, cervical and endometrial carcinomas using real-time quantitative RT-PCR. Br J Cancer 2000 82 1682 8.
16. Teerds KJ Dorrington JH. Immunolocalization of transforming growth factor alpha and luteinizing hormone receptor in healthy and atretic follicles of the adult rat ovary. Biol Reprod 1995 52 500 8.
17. Scholzen T Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000 182 311 22.
18. Soini Y Paakko P Lehto VP. Histopathological evaluation of apoptosis in cancer. Am J Pathol 1998 153 1041 53.
19. Quirk SM Cowan RG Huber SH. Fas antigen-mediated apoptosis of ovarian surface epithelial cells. Endocrinology 1997 138 4558 66.
20. Fenton RG Hixon JA Wright PW Brooks AD Sayers TJ. Inhibition of Fas (CD95) expression and Fas-mediated apoptosis by oncogenic Ras. Cancer Res 1998 58 3391 400.
21. Sheard MA Vojtesek B Janakova L Kovarik J Zaloudik J. Up-regulation of Fas (CD95) in human p53wild-type cancer cells treated with ionizing radiation. Int J Cancer 1997 73 757 62.
22. Bell DA Scully RE. Early de novo ovarian carcinoma. A study of fourteen cases. Cancer 1994 73 1859 64.
23. Feeley KM Wells M. Precursor lesions of ovarian epithelial malignancy. Histopathology 2001 38 87 95.
24. Resta L Russo S Colucci GA Prat J. Morphologic precursors of ovarian epithelial tumors. Obstet Gynecol 1993 82 181 6.
25. Dubeau L. The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: does the emperor have no clothes? Gynecol Oncol 1999 72 437 42.
26. Baldwin RL Tran H Karlan BY. Primary ovarian cancer cultures are resistant to Fas-mediated apoptosis. Gynecol Oncol 1999 74 265 71.
27. Ghahremani M Foghi A Dorrington JH. Activation of Fas ligand/receptor system kills ovarian cancer cell lines by an apoptotic mechanism. Gynecol Oncol 1998 70 275 81.
28. Guo MW Mori E Xu JP Mori T. Identification of Fas antigen associated with apoptotic cell death in murine ovary. Biochem Biophys Res Commun 1994 203 1438 46.
29. Kim JM Yoon YD Tsang BK. Involvement of the Fas/Fas ligand system in p53-mediated granulosa cell apoptosis during follicular development and atresia. Endocrinology 1999 140 2307 17.
30. Kondo H Maruo T Peng X Mochizuki M. Immunological evidence for the expression of the Fas antigen in the infant and adult human ovary during follicular regression and atresia. J Clin Endocrinol Metab 1996 81 2702 10.
31. Leithauser F Dhein J Mechtersheimer G et al. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 1993 69 415 29.
32. Ben Hur H Gurevich P Huszar M et al. Apoptosis and apoptosis-related proteins (Fas, Fas ligand, Blc-2, p53) in lymphoid elements of human ovarian tumors. Eur J Gynaecol Oncol 2000 21 53 7.
33. Zusman I Gurevich P Gurevich E Ben Hur H. The immune system, apoptosis and apoptosis-related proteins in human ovarian tumors (a review). Int J Oncol 2001 18 965 72.
34. O'Connell J Bennett MW O'Sullivan GC Collins JK Shanahan F. The Fas counterattack: cancer as a site of immune privilege. Immunol Today 1999 20 46 52.